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Abstract
Current cell-based assays for determining the functional properties of high-density lipoproteins (HDL) have limitations. We
report here the development of a new, robust fluorometric cell-free biochemical assay that measures HDL lipid peroxidation
(HDLox) based on the oxidation of the fluorochrome Amplex Red. HDLox correlated with previously validated cell-based
(r = 0.47, p,0.001) and cell-free assays (r = 0.46, p,0.001). HDLox distinguished dysfunctional HDL in established animal
models of atherosclerosis and Human Immunodeficiency Virus (HIV) patients. Using an immunoaffinity method for
capturing HDL, we demonstrate the utility of this novel assay for measuring HDLox in a high throughput format.
Furthermore, HDLox correlated significantly with measures of cardiovascular diseases including carotid intima media
thickness (r = 0.35, p,0.01) and subendocardial viability ratio (r =20.21, p = 0.05) and physiological parameters such as
metabolic and anthropometric parameters (p,0.05). In conclusion, we report the development of a new fluorometric
method that offers a reproducible and rapid means for determining HDL function/quality that is suitable for high
throughput implementation.
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Introduction
There is a continuing search for new biomarkers of atheroscle-
rotic disease. Manipulation of HDL has great potential in reducing
cardiovascular risk; however, studies in humans suggest a complex
relationship between HDL and atherosclerosis [1,2]. Lower HDL
values are not uniformly associated with excess cardiovascular risk
while higher HDL levels may not always confer a protective
benefit [1,2]. Measuring HDL cholesterol levels provides infor-
mation about the size of the HDL pool, but does not predict HDL
composition or function. Thus, HDL function rather than absolute
level may be a more accurate indicator of cardiovascular risk [1,2].
Due to the complexity of the HDL particles, measurement of
HDL function has not been studied extensively in humans [3,4].
Robust assays to evaluate the function of HDL are needed to
supplement the measurement of HDL cholesterol levels in the
clinic. Currently, HDL functional properties are most often
determined by cell-based assays including the measurement of
cholesterol efflux capacity [5–8]. However, several limitations
render these cell-based assays inaccessible to many researchers and
difficult to scale up for large-scale clinical trials and/or routine
clinical use [9].
HDL oxidation may contribute to the formation of dysfunc-
tional HDL [10,11] and we have previously shown that the
oxidative properties of HDL are closely associated with HDL
function [12]. Along these lines, we previously developed a cell-
free assay that measures HDL function by testing the effect of
HDL on the production of reactive oxygen species (ROS) after
oxidation and conversion of dichlorodihydrofluorescein diacetate
(DCFH-DA) to fluorescent DCF (2’,7’-dichlorofluorescein) [13].
Although this assay has been used in several studies in humans to
study HDL function [3,4,14–19] and a modified version of this
assay has been described [20,21], it has not found widespread
usage due to the oxidative instability of DCFH-DA. We developed
an alternative biochemical assay to quantify the HDL redox
activity (HRA) that measures the products of redox cycling as the
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rate of oxidation of the fluorogenic probe dihydrorhodamine-123
(DHR) to fluorescent rhodamine 123 [12]. Despite the relative
stability of DHR in contrast to DCF, it was realized that the
complexity of the matrix-lipid-probe-ROS interactions in the
setting of systemic inflammation might complicate interpretation
of the results using the DHR assay [12,22].
We now describe a new assay to quantify HDL lipid
peroxidation (HDLox), a measure of HDL function, in a cell-
free biochemical assay. Amplex Red reagent in the absence of
cholesterol oxidase and in the presence of horseradish peroxidase
(HRP) specifically quantifies the endogenous lipid hydroperoxides
of a specific amount of HDL cholesterol. We demonstrate that this
approach, in combination with immunoaffinity capture of HDL
for HDL isolation, overcomes the confounding factors that
affected the readout in the previously described cell free assays
of HDL function [12,22].
Materials and Methods
Reagents
Dihydrorhodamine 123 (DHR) was obtained from Molecular
Probes (Eugene, OR). DHR was prepared as concentrated stock of
50 mM in dimethyl sulfoxide (DMSO) as previously described
[12]. Iron-free HEPES (N-2-hydroxyethylpiperazine-N’-2-ethane-
sulfonic acid)-buffered saline (HBS, HEPES 20 mM, NaCl
150 mM, pH 7.4) was prepared as previously described [12].
The DHR stock was diluted 1:1000 in HEPES saline solution to
prepare a working solution of 50 mM. Reagents from the Amplex
Red Cholesterol Assay Kit (Catalog number A12216, Life
Technologies, Grand Island, NY) were used for the new assay.
These reagents included the Amplex Red reagent (10-acetyl-3,7-
dihydroxyphenoxazine), Hydrogen Peroxide (H2O2) working
solution, Resorufin fluorescence reference standard, horseradish
peroxidase (HRP), Cholesterol esterase, reaction buffer (0.5 M
potassium phosphate, pH 7.4, 0.25 M NaCl, 25 mM cholic acid,
0.5% Triton X-100). 13(S)-hydroperoxy-9Z, 11E-octadecadienoic
acid (13(S)-HPODE) was purchased from Cayman Chemicals
(Ann Arbor, MI, USA). Pravastatin sodium (Lot No. M000301,
Catalog number P6801) was purchased from LKT Laboratories,
Inc.
HDL and LDL purification and oxidation
HDL and LDL were isolated from cryopreserved human
plasma (with or without added sucrose) by ultracentrifugation, fast
performance liquid chromatography (FPLC), or precipitation with
polyethylene glycol as previously described [12,23–26]. HDL was
also oxidized in vitro with 13(S)-HPODE as described [16]:
human HDL (5 mg HDL-cholesterol/ml) was incubated with
13(S)-HPODE (0.5 mg/ml), for 60 min (co-incubation).
Immunoaffinity capture of HDL
We have previously used immunoaffinity capture of HDL to
study changes in the proteome associated with dysfunctional HDL
[14,18,19]. Briefly, 96-well polyvinyl chloride microfilter plates
(BD Biosciences) were precoated with 1–5 mg/ml of chicken anti-
human HDL antibodies (GenWay Biotech, San Diego, CA)
overnight at 4uC. Following incubation of the pre-coated plates
with individual plasma samples diluted at 1:10 with 1X PBS,
serum at 1:20 dilution, or HDL at 1:2 dilution, the plates were
washed thoroughly. Detection of HDL was confirmed by HDL-
capturing sandwich enzyme-linked immunosorbent assays (ELISA)
as described previously using corresponding primary antibodies to
human ApoA-I at 1:2,500 dilution [14,18,19]. In addition, total
HDL was captured using polyclonal antibodies included in 5
commercially available kits [Genway Inc (kit A); Biotang Inc (kit
B), Cusabio Inc (kit C), China; WKEA Inc, China (kit D); Wuhan
EIAab., Ltd; China (kit E)) according to the manufacturers’
instructions.
Measurement of HDL cholesterol
HDL cholesterol was quantified using a standard colorimetric
assay (Thermo DMA Co., San Jose, CA, USA) as previously
described [12]. Samples were also assayed by the UCLA Clinical
Laboratory for total cholesterol, high-density lipoprotein (HDL),
non-HDL cholesterol and triglycerides (TG) using the Olympus
AU400 Chemistry Analyzer.
Measurement of total HDL protein
The total HDL protein ‘‘captured’’ in each well was measured
using the BCA Protein Assay as previously described [14,17–19].
In addition, the total HDL protein concentration for each sample
was measured using total HDL ELISA and the above commer-
cially available kits (Kits A, B) according to the manufacturer’s
instructions.
Detection of albumin
50 ml of plasma (n= 10) was added into 96 wells and was
isolated using immunoaffinity capture of HDL according to the
manufacturer’s instructions (Kit A). After 5 washes, 300 ml of
albumin bromocresol green reaction (BCG) reagent (Thermo
Scientific Inc) were added to each well and after 90 second
incubation at 37uC optical density was measured at 630 nm.
Results are expressed as % relative value compared to the positive
control (50 ml of plasma). Detection of albumin was also confirmed
by albumin ELISA according to the manufacturer’s instructions
(Pierce) using corresponding antibodies to human albumin
conjugated to HRP.
HDL inflammatory index
The HDL-inflammatory index (HII) was determined for each
subject’s HDL as described previously [8,13]. Values in the
absence of HDL were normalized to 1.0. The values obtained in
the presence of the test HDL were divided by the value obtained in
the absence of HDL to yield the HII. Values .1.0 after the
addition of the test HDL indicated proinflammatory HDL; values
,1.0 indicated anti-inflammatory HDL.
DHR-based cell-free assay of HDL function
The DHR assay was performed as previously described [12].
Briefly, quadruplicates of HDL (5 mg of cholesterol unless
otherwise specified were added to 96-well plates (polypropylene,
flat bottom, black, Fisher Scientific, USA). HBS was added to
each well to a final volume of 150 ml, followed by addition of
25 ml of the working solution of 50 mM DHR, for a total volume
of 175 ml. Immediately following DHR addition, the plate was
protected from light, placed in the fluorescence plate reader and
fluorescence of each well was assessed at two minute intervals for
an hour with a Synergy 2 Multi-Mode Microplate Reader
(Biotek, Vermont, USA), using a 485/538 nm excitation/
emission filter pair with the photomultiplier sensitivity set at
medium. The oxidation rate was calculated for each well as the
slope for the linear regression of fluorescence intensity over
60 minutes, expressed as FU minute-1 (fluorescence units per
minute). HDLox was calculated as the mean of quadruplicates for
the wells containing the HDL sample.
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Amplex red assay
Method A: Use of PEG precipitation for HDL
isolation. ApoB depleted serum was isolated from human
plasma using PEG precipitation and then a specific amount of
HDL cholesterol (5 mg; quantified using a standard colorimetric
assay, Thermo, CA, USA) was added to 96-well plates (polypro-
pylene, flat bottom, black, Fisher Scientific, USA) in quadrupli-
cates with the appropriate volume of 1X reaction buffer for a total
volume of 50 ul per reaction well. A 2 mM resorufin solution was
used to prepare a standard curve to determine the moles of
product produced in the Amplex Red reaction. The appropriate
amount of 2 mM resorufin reference standard was diluted into 1X
reaction buffer to produce resorufin concentrations of 0 to
,20 mM). 1X reaction buffer without cholesterol was used as a
negative control. A 20 mM H2O2 working solution was used as a
positive control. A volume of 50 mL was used for each reaction.
50 ml of HRP/catalase solution containing 1–10 U/mL HRP and
1–4 U/ml catalase was then added followed by an incubation for
60 minutes. 50 ml of 300 mM of Amplex Red reagent (Invitrogen)
containing 0.2 U/mL cholesterol esterase were then added to each
microplate well containing the samples and controls. The
fluorescence of each well was assessed at one-minute intervals
over 60 minutes with a plate reader (Biotek, Vermont, USA), using
a 530/590 nm filter pair. The fluorescence at each timepoint can
be expressed as: 1) relative to the maximum fluorescence observed
over 60 minutes 2) relative to fluorescence of the corresponding
timepoint of a reference control sample 3) as specific concentration
of resorufin (mM) extrapolated from the resorufin standard curve at
the specific timepoint using 4 parameter logistic regression
analysis. The slope of the reaction of the Amplex Red reagent
with the endogenous hydroperoxides present in HDL in the
absence of cholesterol oxidase, corresponds to the endogenous
HDLox of each sample and was calculated over 60 min using the
Gen5 2.01 software (Biotek, Vermont, USA). Alternatively, a
specific volume (50 ml) of apoB-depleted serum was added in each
well in quadruplicates and the mean fluorescence readout (slope)
was normalized by the HDL cholesterol concentration of each
sample as measured by the clinical lab (mg/dL). A buffer blank
was measured in each assay, and the fluorescence readout in the
buffer blank was subtracted from each sample. The plate was
protected from light during the assay to minimize artifactual
oxidation by light. A step by step description of the assay is
provided in Table S1 and Figure S1.
Method B: Use of HDL immunocapture for HDL
isolation. The following matrices were used for HDL capture
in 96 well plates: 1) specific amount of commercially available
purified HDL (Sigma) (5 mg of HDL cholesterol) 2) specific
amount of purified HDL isolated by ultracentrifugation (5 mg of
HDL cholesterol) 3) specific amount of apo-B depleted serum
isolated by PEG precipitation (5 mg of HDL cholesterol) 4) specific
volume of plasma or serum (100 ml) 5) specific volume of apo-B
depleted serum (100 ml). These matrices were then added into 96
wells and HDL was isolated using immunoaffinity capture of HDL
as described in Methods. The Amplex Red assay was performed as
described above. When a specific volume (100 ml) of apoB-
depleted serum or plasma/serum was added in each well in
quadruplicates, the mean fluorescence readout (slope) was
normalized by the HDL cholesterol concentration of each sample
as measured by the clinical lab (mg/dL).
Human subjects
Subjects with coronary artery disease (CAD). Blood
samples were collected from patients with coronary artery disease
(CAD) or equivalent as defined by the National Cholesterol
Education Program Adult Treatment Panel III criteria [27] and
were collected from patients referred to the cardiac catheterization
laboratory at the Center for Health Sciences at the University of
California, Los Angeles. After signing a consent form approved by
the Human Research Subject Protection Committee of the
University of California, Los Angeles, the patient donated a
fasting blood sample collected in a heparinized tube. Plasma
samples were also randomly selected from pre-treatment samples
remaining from a previously described study in which all patients
had coronary artery disease or equivalent [8]. All of these patients
were on a statin [8].
Human Immunodeficiency Virus (HIV-1)-infected
individuals. Fifty HIV-1-infected individuals on combination
antiretroviral therapy (ART) with suppressed viremia (below 50
copies of RNA/ml) (48 males and 2 females; median age 44, range
18–53 years) were recruited at the University of California, Los
Angeles (UCLA) as previously described [8]. These patients had
no documented coronary atherosclerosis and normal total
cholesterol (200 mg/dl), LDL cholesterol (130 mg/dl), HDL
cholesterol (males, .45 mg/dl; females, .50 mg/dl), and triglyc-
erides (,150 mg/dl), were not receiving hypolipidemic medica-
tions and were not diabetic. Fifty normal volunteers (42 males and
8 females; median age 42, range 18–57 years), matched by age and
gender, were recruited under a protocol approved by the Human
Research Subject Protection Committee of the University of
California, Los Angeles (UCLA IRB). Blood samples from a
previously completed matched cohort study that was designed to
investigate the role of ART therapy and HIV-1 infection on the
risk for subclinical atherosclerosis and its progression were also
used for validation of the new assay; the study design has been
previously published [28]. In this cohort subjects were enrolled as
risk factor (age, sex, race/ethnicity, smoking status, blood pressure,
and menopause status)-matched triads of HIV-1-infected individ-
uals with viremia ,500 RNA copies/ml with (n = 29) or without
(n = 26) use of protease inhibitor (PI) therapy, and HIV-1-
uninfected subjects (n = 36).
Healthy subjects. Blood bank specimens were collected from
healthy young blood donors according to previously well-defined
criteria [29–31]. More specifically the donors were young (range
19–40 years old) had no known underlying diseases including
diabetes, were known to have normal lipid profile and were not
receiving hypolipidemic medications.
Exercise study participants. In this cross sectional study,
90 young adult males, ages of 18–30 were recruited and
categorized into 3 phenotypes based on training status and Body
Mass Index (BMI): lean trained (LT, n= 30,$4 d/week resistance
training (RT), BMI,25 kg/m2), overweight trained (OT, n= 30,
$4 d/week RT, BMI.27 kg/m2) and overweight untrained
populations (OU, n= 30, no structured exercise regimen, BMI.
27 kg/m2). Overweight untrained subjects participated in only
light intensity physical activity #2 times/wk. Participants with
overt chronic disease symptoms, as indicated by screening,
comprehensive history and/or physical examination, were exclud-
ed from the study. Potential participants who had documented
cardiovascular disease or used tobacco products or medications
that influence cardiovascular function, body composition or
insulin indices in the prior 6 months were excluded from the
study. All of the study protocols were approved by the UCLA IRB.
Mice
ApoE and LDLR null mice originally purchased from the
Jackson Laboratories on a C57BL/6J background were obtained
from the breeding colony of the Department of Laboratory and
Animal Medicine at the David Geffen School of Medicine at
A Fluorometric Method for Measurement of HDL Function
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UCLA as previously described [32]. The mice were maintained on
a Western diet (Teklad, Harlan, catalog # TD88137) for 2 weeks
and a group of mice was also treated with pravastatin at 12 mg/ml
drinking water, or approximately 50 mg per day for two weeks. All
experiments were performed using protocols approved by the
Animal Research Committee at UCLA.
Data collection
Metabolic syndrome was defined by National Cholesterol
Education Program (NCEP) criteria [27]. In the HIV cohort
fasting glucose, insulin, lipids, high-sensitivity C-reactive protein
(hs-CRP), cardiovascular disease-related measurements, CD4+ T
cell counts and HIV-1 RNA levels were previously determined
[28]. Carotid artery intima-media thickness (CIMT) of the far
wall of the right common carotid artery was measured at baseline
and longitudinally as previously published [28]. In the exercise
study measurements of serum glucose, serum insulin, homeostasis
model assessment for insulin resistance (HOMA), oxLDL, hs-
CRP, body composition parameters, anthropometric parameters,
blood pressure (i.e. brachial systolic and diastolic pressure, bSBP,
bDBP) maximal strength testing, subendocardial viability ratio
(SEVR) were performed as previously described [33].
Statistical analysis
Statistical analyses were performed with the use of Stata
statistical software 12 (StataCorp LP., College Station, TX).
Group means were compared using the Student’s t-test for
unpaired variates with p,0.05 considered to be statistically
significant. Correlation coefficients between variables were calcu-
lated using least squares linear regression. In the HIV cohort,
conditional logistic regression modeling for matched pairs data
stratified by triad evaluated associations with CIMT progression.
Figure 1. Principle of the Amplex Red assay of HDL function. 1. The acute-phase (AP) reaction favors the formation of dysfunctional HDL. In
the basal state, HDL contains apoA-I and apoJ as well as 4 enzymes, paraoxonase (PON) and platelet-activating factor acetylhydrolase (PAF-AH),
lecithin: cholesterol acyltransferase (LCAT), and plasma reduced glutathione selenoperoxidase (GSH peroxidase) that can prevent the formation of or
inactivate the LDL-derived oxidized phospholipids found in oxidized LDL. As a result, in the basal state, HDL may be considered anti-oxidant. As
previously published (Navab M et al. Arterioscler Thromb Vasc Biol 2001; 21: 481–488), during the acute-phase reaction, A-I may be displaced by the
pro-oxidant acute-phase reactant Serum amyloid A (SAA). Another pro-oxidant acute-phase reactant, ceruloplasmin, associates with HDL as does the
anti-oxidant acute phase reactant apoJ. PON, PAF-AH, and LCAT decrease in HDL during the acute-phase reaction, and the lipid hydroperoxides
(LOOH) 5-hydroperoxyeicosatetraenoic acid (HPETE), hydroperoxyoctadecadienoic acid (HPODE), and cholesteryl linoleate hydroperoxide (CE-OOH)
increase in HDL. The net effect of the changes in HDL during the acute-phase reaction is the production of pro-oxidant, HDL particles (AP-HDL or
dysfunctional HDL). 3. HDL can be isolated using different methods such as ultracentrifugation, PEG precipitation and immunoaffinity capture. Using
immunoaffinity capture of HDL and commercially available antibodies against total human HDL, HDL is isolated from a specific volume (e.g. 100 ul) of
either a) non EDTA plasma b) serum or c) apoB depleted serum 4. Amplex Red (N-acetyl-3, 7-dihydroxyphenoxazine) reagent is a colorless substrate
that reacts with hydrogen peroxide (H2O2) in the presence of horseradish peroxidase (HRP) with a 1:1 stoichiometry to produce highly fluorescent
resorufin (excitation/emission maxima =570/585 nm). This highly stable, sensitive and specific fluorogenic substrate for HRP has been widely used to
develop a variety of fluorogenic assays for enzymes that produce hydrogen peroxide. For example Amplex Red reagent coupled with the enzymes
cholesterol oxidase and HRP permit the ultrasensitive quantitation of HDL cholesterol based on lipid peroxidation. The biochemistry of lipid
peroxidation has been well established (Free Radical Research 2010:44, 1098–1124) and during this reaction there is formation of reactive oxygen
species (ROS) such as peroxyl and alkoxyl radicals (ROO-, RO-; LOOH-) that have previously been shown to react with the Amplex Red reagent to form
fluorescent resorufin ((J. Biol. Chem. 284, 46–55; J Biol Chem. 2010 May 28; 285(22): 16599–605). Resorufin is produced by the reaction of the Amplex
Red reagent with H2O2 produced from the cholesterol oxidase-catalyzed oxidation of cholesterol. In the absence of cholesterol oxidase, the
‘‘endogenous’’ hydroperoxide content of a specific amount of HDL cholesterol can be quantified in the presence of HRP and Amplex Red. High
hydroperoxide content of a specific amount of HDL cholesterol has previously been shown to be significantly associated with abnormal HDL
function. The background production of hydroxyradicals as a result of air oxidation of the buffer (based on the readout of the blank well that contains
Amplex Red reagent and buffer) is subtracted from the fluorescent readout of each well. In addition, to better evaluate the LOOH-dependent
oxidation, catalase (not shown in figure) may be added in the medium to remove rapidly the formed H2O2 so that the detected increase in
fluorescence may be attributed mainly to lipid LOOH release.
doi:10.1371/journal.pone.0111716.g001
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Covariates significant in the univariate analysis (p,0.05) were
examined together in multivariate analysis. In the exercise study,
post-hoc Pearson correlation analyses were used to determine the
relationships between HDLox and cardiovascular and metabolic
disease risk biomarkers.
Results
Amplex Red can specifically measure lipid peroxidation
of a specific amount of HDL
Amplex Red in the presence of the enzyme cholesterol oxidase
has been reliably used to quantify cholesterol content of HDL
based on lipid peroxidation of HDL [34,35]. The biochemical
reaction of the Amplex Red Reagent in the presence of HRP and
H2O2 to produce highly fluorescent resorufin and measure
peroxides is well established [34,35]. Horseradish peroxidase is
known to catalyze both the H2O2- and LOOH-dependent
oxidation of non-fluorescent Amplex Red to fluorescent resorufin
red [36,37]. Thus, to evaluate the LOOH-dependent oxidation,
catalase may be added in the incubation medium to remove
rapidly the formed H2O2 so that the detected increase in
fluorescence may be attributed to lipid LOOH release [36,37].
Using a modification of a previously published method that was
used to measure lipid hydroperoxide content [36,37], we detected
HDL LOOH release using Amplex Red, horseradish peroxidase,
and catalase. In the absence of cholesterol oxidase and in the
presence of HRP and catalase, Amplex Red specifically quantifies
the endogenous lipid hydroperoxides of a specific amount of
HDL cholesterol (Fig. 1). Using this modification (no cholesterol
oxidase), for the same amount of HDL cholesterol differences in
the rate of lipid peroxidation between different samples (as
detected by the Amplex Red reagent) would correspond to
differences in HDL lipid peroxidation (Fig. 1).
Lipid probe interactions are still present when using
Amplex Red in fluorescent assays of HDL function
Since use of fluorescent assays of HDL function may allow study
of the role of the functional phenotype of HDL in the setting of
large scale studies [12] especially with the use of a robust,
reproducible, high throughput method to extract HDL from
patient serum such as PEG precipitation [4], we determined the
(apo) B-depleted serum-Amplex Red interactions in patients with
inflammatory conditions such as HIV versus healthy subjects.
Without HDL, Amplex Red exposed to air became oxidized (and
therefore fluorescent) at a linear rate within 60 minutes. The rate
of oxidation of Amplex Red was significantly less with added
HDL, and different HDL samples (from patient with dysfunctional
HDL compared to healthy subjects) showed clearly different effects
in this regard (Fig. S2). Thus, apoB depleted serum-probe
interactions were also present with Amplex Red similarly to the
previously used fluorescent probes [22].
Use of Amplex Red in combination with HRP overcomes
lipid probe interactions when measuring lipid
peroxidation of HDL
To determine whether the reduction in the fluorescence signal
of Amplex Red after addition of HDL can be minimized or
abolished by adding an enzyme that specifically catalyzes the lipid
peroxidation and the oxidation of Amplex red [38–40], we tested
the effect of addition of different concentrations of HRP on the
oxidation rate of Amplex Red in the presence of a specific
amount of HDL cholesterol. Determination of the rate of
production of resorufin was performed by measuring the slope
of fluorescence increase during the first 60 minutes, when the rate
of oxidation is linear (Fig. S3). Increasing concentrations of HRP
0.5–4 U/ml increased the oxidation rate of Amplex Red in the
setting of lipid peroxidation of specific amount of HDL,
compared to when Amplex Red was used without any HRP
(Fig. S2). These differences could be demonstrated using both
purified HDL isolated by ultracentrifugation and FPLC and apoB
depleted serum (Fig. S2), a matrix that is characterized by more
prominent lipid probe interactions [22]. Addition of catalase (1–
4 U/ml) did not significantly change the relative differences in
HDLox between different groups of samples (dysfunctional HDL
versus normal HDL). Thus, HDLox can be quantified with the
use of Amplex Red and HRP with minimal lipid-probe
interactions.
Amplex Red can reliably measure lipid peroxidation of a
specific amount of HDL (HDLox)
We used Amplex Red in the presence of HRP to specifically
quantify the rate of lipid peroxidation (HDLox) of a specific
amount of HDL cholesterol. The Amplex Red assay could detect a
concentration dependent increase in the amount of hydroperox-
ides associated with increasing amount of added HDL cholesterol
(Fig. S4). In addition, the Amplex Red assay could reliably
quantify the content of hydroperoxides associated with a specific
amount of HDL cholesterol (Fig. 2). Finally, the Amplex Red
could reliably measure HDLox with low interassay and intra-assay
experimental variability (,11%) (Fig. S5), irrespective of the HDL
isolation (Fig. S6).
The Amplex Red assay can detect dysfunctional HDL
in vivo
To further validate the new method we used the Amplex Red
assay to detect dysfunctional HDL in conditions in which
dysfunctional HDL is known to be present such as established
animal models of atherosclerosis [12,14], and Human Immuno-
deficiency Virus infection (HIV) [12]. The Amplex Red assay
could detect established effect of statins on functional properties of
HDL in animal models of atherosclerosis such as LDLR2/2
(Fig. 3a) and ApoE2/2 mice (Fig. 3b). In addition, using samples
from a previous cohort of HIV patients known to have
dysfunctional HDL by using previously established assays of
HDL function [12,22], the Amplex Red assay confirmed that these
patients had higher HDLox compared to healthy controls (Fig. 4).
Thus, using this methodology we demonstrate that HDL from
patients with dysfunctional HDL has a higher rate of lipid
peroxidation of a specific amount of HDL (HDLox) compared to
HDL from healthy patients.
Results from the Amplex Red assay correlate with
previously validated cell-based and cell-free assays
To compare the results of the Amplex Red assay to those
obtained using a validated cell-based assay [8,12] 30 HDL samples
were assessed using both assays (Fig.5). Comparing HDLox as
measured with Amplex Red to the HDL inflammatory index,
there was a significant positive correlation (r = 0.47, p,0.001).
Moreover, to compare the results of the Amplex Red assay to
those obtained using a validated cell-free assay [12] 60 HDL
samples were assessed using both assays (Fig. 6). HDLox as
measured with Amplex Red correlated significantly to the HDLox
as measured with DHR (r = 0.46, p,0.001).
A Fluorometric Method for Measurement of HDL Function
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Standardization of the Amplex Red assay of HDL function
The lack of standardization of assays of HDL function may
limit comparison of results between studies. An Amplex red stock
solution of resorufin can be used to prepare a standard curve to
determine the moles of product produced in the Amplex Red
reaction [35,41]. Using this approach the fluorescence readout
that corresponds to HDLox can be expressed as the rate of
formation of specific amount of resorfurin per specific unit of time
(e.g. mM resorfurin/min) and this readout can be directly
compared among different experiments especially since all the
reagents used in the Amplex red assay, including all buffers, are
commercially available and accessible to all researchers (Fig. S7).
We also used a control sample which is prepared from pooled
HDL samples isolated from plasma blood bank specimens to
standardize the assay (similarly to INR, International Normalized
Ratio) as previously [42](Figs. S8, S9). Since eligibility criteria for
blood bank donors are well defined worldwide [29–31], this
approach may be used to create a universal control even when
pooled controls from different blood banks are used to compare
results of assays of HDL function between different studies (Fig.
S8). The use of this control may also aid in controlling for
unforeseen and unaccounted-for variables that may be affecting
the readout including matrix effects and artifactual oxidation.
Finally the Amplex Red assay can be further standardized by using
the HDL concentration as determined by the clinical laboratory (a
well-standardized measurement) rather than the HDL cholesterol
concentration as determined by a cholesterol assay (as described in
Methods) to adjust the fluorescence readout for the amount of
HDL cholesterol in each sample (Fig. S10).
Freeze-thaw can affect HDLox as measured by the
Amplex Red assay
Similar to our previous results, [12,22] we found that
cryopreserved samples up to one freeze-thaw cycle can reliably
be used to determine HDLox in the Amplex red assay [22] (Figure
S11). The standardization method with the pooled control may
minimize the effect of multiple freeze-thaw cycles on determina-
tion of HDLox using the Amplex Red assay (Fig. S11).
Matrix effects can affect HDLox as measured by the
Amplex Red assay
Similar to our previous methodology [12,22], we have
confirmed the effects of different matrices such as plasma or
serum on biochemical assays of HDL function and we conclude
that plasma citrate or serum should be best used to determine
HDL redox activity in the Amplex red assay since heparin and
EDTA can affect determination of ROS in biological fluids
[43](Fig. S12). The standardization method with the pooled
control tended to minimize the effect of different matrices on
determination of HDLox (Fig. S12).
Sample handling and long term cryopreservation can
affect HDLox as measured by the Amplex Red assay
We then determined the effects of long-term storage of blood
specimens at 280C on HDLox. We found that long-term storage
Figure 2. Assay performance. A. Linearity of the Amplex Red Assay of HDL lipid peroxidation when#10 ug of HDL cholesterol is added. HDL was
isolated by ultracentrifugation from 3 HIV infected patients known to have acute phase HDL (AP-HDL) and 3 patients with normal HDL (as
determined using a previous assay of HDL function; J Lipid Res. 2011; 52: 2341–51). HDL was then added in varying concentrations (cholesterol) to
300 mM Amplex Red in a 96 well flat bottom plate and the rate of change in fluorescence was measured as in Figure S2 in the presence of 4 U/ml of
HRP. The rates of change in fluorescence were normalized against the added HDL cholesterol amount (in mg of cholesterol as determined by a
cholesterol assay) and are plotted (means and standard deviations) against the amounts of added HDL. Similar results were observed when HDL
cholesterol isolated by PEG precipitation was added to the reaction. B. The linearity of the assay was also demonstrated using in vitro oxidation of
HDL by adding increasing amounts of pre-formed lipid peroxides. In vivo studies have shown that 13(S)-H(P)ODE is an in vivo generated lipid oxidant
that has a key role in atherogenesis and contributes to formation of dysfunctional HDL (Drug Metab Lett. 2010; 4: 139–48). HDL from 3 different
healthy subjects (1 mg) was oxidized in vitro with increasing amounts of HPODE as previously described (Drug Metab Lett. 2010; 4: 139–48). Increasing
amounts of 13(S)-H(P)ODE linearly increased the fluorescence readout using the Amplex Red assay as described in A.
doi:10.1371/journal.pone.0111716.g002
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Figure 3. The Amplex red assay of HDL function can detect established effect of statins on functional properties of HDL in animal
models of atherosclerosis. A: By using FPLC, HDL was isolated from three pooled plasma samples from LDLR2/2 mice on Western diet (LDLR2/2
WD) for two weeks and from three pooled plasma samples from LDLR2/2mice on Western diet for two weeks that were also treated with pravastatin
12.5 mg/ml for two weeks. Each plasma sample was pooled from 4 mice (12 mice in total). Oxidation of Amplex Red was assessed as in Figure 2, using
2.5 mg (cholesterol) of added HDL. The oxidation slope of Amplex Red in the presence of HDL from LDLR2/2 WD + statin was normalized to the
oxidation slope of Amplex Red in the presence of HDL from LDLR2/2 WD, and the percent relative differences are shown. The data represent the
average of measurements from three independent experiments. There was a statistically significant reduction in the oxidation slope of Amplex Red in
the presence of HDL isolated from LDLR2/2WD + statin mice compared with the oxidation slope of DHR in the presence of HDL isolated from LDLR2/
2 WD mice (** P=0.01) B: By using FPLC, HDL was isolated from three pooled plasma samples from ApoE2/2 female mice on Western diet (ApoE2/2
WD) for two weeks and from three pooled plasma samples from ApoE2/2 female mice on Western diet for two weeks that were also treated with
pravastatin 12.5 mg/ml for two weeks. Each plasma sample was pooled from 4 mice (12 mice in total). Oxidation of Amplex Red was assessed as in A.
There was a statistically significant reduction in the oxidation slope of Amplex Red in the presence of HDL isolated from ApoE2/2 WD + statin mice
compared with the oxidation slope of Amplex Red in the presence of HDL isolated from ApoE2/2 WD mice (** P=0.01).
doi:10.1371/journal.pone.0111716.g003
Figure 4. The Amplex Red Assay of HDL function can detect
acute phase HDL in vivo in subjects previously shown to have
dysfunctional HDL. ApoB depleted serum was isolated by PEG
precipitation from 50 healthy subjects and 100 patients with HIV
infection and that have previously been shown to have acute phase
HDL (Lipids Health Dis 2012; 11: 87). The Amplex Red oxidation rate
(AROR) as a marker of HDL redox activity (HDLox) was determined as
described in Figure 2 and Figure S10. The HIV-infected subjects had
significantly higher HDLox (1.5960.53) compared to the uninfected
subjects 1.0160.31) (p,0.001).
doi:10.1371/journal.pone.0111716.g004
Figure 5. The readout from the Amplex Red Assay of HDL
function correlates significantly to the readout of a previously
validated cell based assay of HDL function. Thirty samples of
FPLC-purified HDL were assessed for their HDL redox activity (HDLox)
using the Amplex Red assay as shown in Figure 2, and their HDL
inflammatory index was determined in a cell-based assay as described
in Materials and Methods. The values from each assay are plotted
against each other.
doi:10.1371/journal.pone.0111716.g005
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of blood samples did not significantly change the ability of the
assay to demonstrate relative differences in the HDLox between
different groups of patients (Fig. S13). However, there was a
modest increase in the HDLox of a specific amount of HDL
cholesterol of the same samples that had been stored an additional
year. Thus, although artifactual oxidation of protein and/or lipid
components of HDL and plasma/serum may affect assays that
measure oxidative state of HDL to a certain extent, the relative
differences in the oxidative state of HDL between different groups
can still be quantified using cryopreserved samples. Ideally, freshly
isolated (not cryopreserved) HDL should be used for biochemical
assays of HDL function that measure HDLox.
The immunoaffinity capture of HDL can be used in the
Amplex Red assay of HDL function to isolate HDL and
minimize albumin contamination
Although PEG precipitation is a reproducible, high throughput
method to extract HDL from patient serum [4], a major issue with
this method is contamination of the HDL with other plasma
proteins, especially albumin [22,44,45]. We have previously used
immunoaffinity capture of HDL to study changes in the proteome
associated with dysfunctional HDL [14,18,19]. Commercially
available total HDL ELISA kits (Kit A: Genway, San Diego, CA;
Kit B: Biotang Inc, Waltham, MA) can be used to capture HDL in
96-well plates when a specific volume of blood, purified HDL or
apo-B depleted serum is added. Using immunoaffinity capture of
HDL and 2 different methods to detect albumin content, we
showed that the HDL captured on 96-well plates is largely free of
albumin (Fig. S14).
Amplex Red can reliably measure lipid peroxidation of a
specific amount of HDL isolated using immunoaffinity
capture of HDL
Using this methodology with different matrices we demonstrate
that HDL from patients with dysfunctional HDL has a higher rate
of lipid peroxidation of a specific amount of HDL compared to
HDL from healthy patients (Fig. 7). However, since the proteome
of dysfunctional HDL has not been fully elucidated [19], it is
possible that dysfunctional HDL may bind less efficiently to
different commercially available HDL antibodies and the total
amount of HDL protein may not be directly compared between
different subjects. Thus, to determine whether the approach of
immunoaffinity capture of HDL depends on the quality of
commercially available HDL antibodies, we used 2 different
commercially available HDL kits with the Amplex Red assay (kit A
and B) to measure HDLox in 60 samples. We found comparable
results (Fig. 8) which indicate that the detected differences in
HDLox are real and not artificial secondary to variations in
binding of HDL to the antibody. Thus, the suggested method may
allow high throughput isolation of HDL and in situ detection of
HDLox that is associated with HDL function.
The Amplex Red-based assay of HDLox in combination
with HDL immunocapture yields reproducible
measurements
To assess which commercially available HDL antibody used to
capture HDL in 96-well plates gives the least experimental
variability, 5 HDL samples were assessed in four independent
experiments using 5 different commercially available kits (kits A–E
as described in Methods). From all 5 different commercially
available kits, kit B had the least experimental variability with an
interassay variability ranging from 5.2 to 7.8% (mean 6.7%) and
inter-assay variability ranging from 5.4 to 10.5% (mean 8.2%).
Finally, from all the 4 different matrices used for HDL capture as
outlined above, for a specific HDL antibody addition of a specific
volume of plasma (100 ml) gave the least experimental variability,
followed by addition of a specific volume of apoB depleted serum
(100 ml). Thus, using specific volume of plasma as input to 96 well
plates for HDL isolation, kit B for HDL capture, and normali-
zation of the fluorescent readout (that corresponds to HDLox) by
the HDL cholesterol concentration (as measured by the clinical
lab) was the most reproducible method to measure HDLox.
The HDLox as measured with the novel assay has the
potential to be used as a marker of cardiovascular
disease in humans
To validate the utility of the new assay to measure HDLox as a
marker of disease in humans, HDLox was measured blindly using
plasma samples from a previously described cohort of 55 HIV
infected subjects and 36 uninfected matched controls [28] and the
Amplex Red assay. We found that HDLox was independently
associated with progression of subclinical atherosclerosis in HIV-
infected subjects (Fig. 9).
The HDLox as measured with the novel assay can be
used as a marker of biologic processes in humans
To further validate the utility of the new assay to measure
HDLox as a marker of HDL function and other physiological
processes in humans, HDLox was measured blindly in a previously
established cohort of 90 subjects that looked into the effect of
exercise on metabolic and other physiological parameters. Using
the serum samples from this study and the Amplex Red assay of
Figure 6. The readout from the Amplex Red Assay of HDL
function correlates significantly to the readout of a previously
validated biochemical cell free assay of HDL function. ApoB
depleted serum was isolated by PEG precipitation from 50 healthy
subjects and 100 patients with HIV infection that have previously been
shown to have acute phase HDL (Lipids Health Dis 2012; 11: 87). HDL
redox activity (HDLox) was determined with the Amplex Red assay as
described in Figure 2 and with the dihydrorhodamine (DHR) assay as
described in Methods. Non cryopreserved apoB depleted serum was
used for the DHR assay and the readout was normalized by the readout
of a pooled control as described in Figure S8. The values from each
assay are plotted against each other (r = 0.46, p,0.001).
doi:10.1371/journal.pone.0111716.g006
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HDL function we found that exercise improved HDL function,
similarly to previous studies (Fig. 10)[46,47]. Additionally, we
assessed associations of HDLox with indices of vascular and
metabolic disease (Fig.11). HDLox (adjusted for HDL cholesterol
concentration as outlined above) had significant negative associ-
ations with the subendocardial viability ratio (r =20.21, p = 0.05),
relative strength (r =20.45, p,0.001), homeostatic model assess-
ment of insulin resistance (r =20.25, p= 0.02), HDL (r =20.92,
p =,0.00001), adiponectin (r =20.29, p,0.01) and significant
positive associations with anthropometric parameters of obesity
such as BMI (r = 0.50, p=,0.0001), waist circumference (r = 0.59,
p =,0.0001), trunk fat (r = 0.56, p =,0.0001), total fat mass
(r = 0.55, p =,0.0001), C-reactive protein (CRP) (r = 0.28, p=,
0.001), fasting glucose (r = 0.23, p = 0.03), fasting insulin (r = 0.21,
p = 0.04), amylin (r = 0.23, p = 0.04), leptin (r = 0.48, p,0.001),
oxidized LDL (r = 0.36, p,0.001), triglycerides (r = 0.36, p,
0.001). These associations remained significant in multivariate
analysis after adjusting for metabolic and anthropometric param-
eters. These pilot data demonstrate our ability to measure HDLox
and associate cardiovascular and metabolic risk phenotypes with
these measures.
Discussion
Growing evidence suggests that HDL varies significantly in its
phenotype and influence on cardiovascular disease risk [1,11].
HDL particles are heterogeneous in shape, density, size, compo-
sition and have multiple functional properties such as reverse
cholesterol transport (RCT), anti-oxidant, anti-inflammatory, and
antithrombotic activities [1]. HDL are ‘‘Janus-like’’ lipoproteins
with the capacity to be anti-inflammatory in the basal state and
proinflammatory during acute-phase responses [1,2]. Previous
work has also suggested dysfunctional HDL to be pronounced in
chronic inflammatory conditions that predispose to atherosclerosis
[2,10,11,48]. This impaired (dysfunctional) HDL, is characterized
by (i) decreased levels and activity of anti-inflammatory, antiox-
idant factors; [1,2] (ii) gain of pro-inflammatory proteins; [49] (iii)
increased lipid hydroperoxide (LOOH) content; [50] (iv) reduced
potential to efflux cholesterol; [51] and (v) diminished ability to
prevent LDL oxidation [52]. Measuring the functional status of
HDL, rather than HDL cholesterol concentration, may be more
informative in predicting cardiovascular disease risk [53]. Unfor-
tunately, the most widely used assays for HDL function have been
cell-based assays [1] which are highly labor-intensive and subject
Figure 7. The Amplex Red Assay of HDL function in combination with immunoaffinity capture of HDL can detect acute phase HDL
in vivo in subjects previously shown to have dysfunctional HDL. HDL was isolated using immunoaffinity capture as described in Methods
from 30 healthy subjects and 30 patients with HIV infection that have previously been shown to have acute phase HDL (Lipids Health Dis 2012; 11:
87). The following different matrices were added in 96 well plates for immunoaffinity capture of HDL: a) purified HDL isolated by ultracentrifugation
(5 mg of HDL cholesterol as determined by cholesterol assay), b) apo-B depleted serum (5 mg of HDL cholesterol as determined by cholesterol assay)
c) apo-B depleted serum (100 ml) d) plasma (100 ml). In the latter two methods, the fluorescent readout (that corresponds to HDLox) was normalized
to the HDL cholesterol concentration (measured by the clinical lab). ApoB depleted serum and plasma was isolated by PEG precipitation and HDL was
also isolated by ultracentrifugation as described in methods. The Amplex Red oxidation rate (AROR) as a marker of HDL redox activity (HDLox) was
determined as described in Figure 2 and Figure S10. The HIV-infected subjects had significantly higher HDLox (A: 1.6660.37; B: 1.5460.32; C:
1.4060.33; D: 1.3260.32) compared to the uninfected subjects (A: 1.0560.28; B: 0.9560.23; C: 0.8160.24; D: 0.7360.24) (p,0.01 for all comparisons).
doi:10.1371/journal.pone.0111716.g007
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to substantial assay variation [5–7] since the optimal method for
performing such studies with regard to donor cells, type of
acceptor and type of readout has yet to be determined. Thus, cell
based assays of HDL function are technically prohibitive,
especially for use in large-scale clinical studies.
Cell-free assays of HDL function may be more precise than cell-
based assays because they measure a biochemical rather than
biologic phenomenon. Thus, we previously developed a cell free
assay based on the fluorochrome DCF that assessed the HDL
inflammatory index (HII), a measure of the capacity of HDL to
prevent the formation or to inactivate oxidized phospholipids
produced by LDL [9]. This was based on our demonstration that
levels of ROS (such as lipid hydroperoxides produced from
oxidation of lipoproteins) are significantly associated with inflam-
matory properties of HDL that are measured by the HII [13]. This
assay has been previously used in multiple studies in humans
[13,54,55] and this measurement of HDL has been associated with
other measures of HDL function such protein biomarkers
associated with dysfunctional HDL [3,4,14–19], HDL anti-
inflammatory function measured as the ability of test HDLs to
inhibit LDL-induced monocyte chemotactic activity in human
aortic endothelial cell monolayers [14,17,19] and measurement of
oxidized fatty acids in HDLs [15,17,56]. It has also been validated
in vivo in animal models of atherosclerosis [15]. Furthermore,
HDL function measured using this assay has been correlated with
systemic inflammation in coronary heart disease (CHD) patients
[16,18] and cardiovascular disease outcome [4,55]. However, the
oxidative instability of DCF-DA, variations in the donor LDL used
in the assay and increased lipid-probe interactions of two
lipoproteins used in the same biochemical reaction increased
experimental variability of this method [18]. Thus, we have
recently developed an assay of HDL function that is based on
DHR, a more stable fluorochrome, in which the endogenous HDL
redox activity is assessed in terms of the capacity of a specific
amount of HDL cholesterol to engage in vitro redox cycling [57].
However, although this assay was validated in vitro [12] and in
Figure 8. Use of different commercially available antibodies
does not affect significantly the immunoaffinity capture of
HDL and determination of HDLox using the Amplex Red assay.
HDL was isolated using immunoaffinity capture as described in
Methods and Figure 7 from 30 healthy subjects (white circles) and 30
patients with HIV infection (solid circles). Two different antibodies were
used (kit A and Kit B) as described in Methods. The Amplex Red
oxidation rate (AROR) as a marker of HDLox was determined as
described in Figure 2 and Figure S10. The values from each assay are
plotted against each other.
doi:10.1371/journal.pone.0111716.g008
Figure 9. Increased HDL redox activity (HDLox), as measured
by the Amplex Red Method and the immunoaffinity capture, is
independently associated with progression of atherosclerosis
in HIV-1- infected subjects in vivo. Scatter plot of the Rate of
Change in Carotid intima–media thickness (CIMT) (DCIMT) and HDLox
for 55 HIV-infected subjects (solid circles) and 36 uninfected controls
(white circles). HDL ELISA kit was used to capture HDL in 96-well plates
(kit B) as described in Methods. HDLox was determined as described in
Figure 2 and Figure S10. The values from HDLox for each subject are
plotted against DCIMT. In multivariate analysis of the HIV-infected
subjects, higher baseline HDLox was associated with the DCIMT
increasing by 2.3 mm/year (95% CI = (0.24, 5.6); p = 0.03) but no
association between DCIMT and HDLox was seen in the controls (not
shown).
doi:10.1371/journal.pone.0111716.g009
Figure 10. The Amplex Red assay of HDL function can detect
previously established favorable effects of exercise on HDL
function. HDLox was measured as described in Figure 2 and Figure
S10 in a cohort of 90 humans looking into the effect of exercise on
metabolic and other physiological parameters. In this study we found
that high-intensity resistance training (RT) improved central and
brachial blood pressures in the overweight untrained (OU) group,
while having no effect on major indices of arterial stiffness in
overweight/obese young men, without weight loss. Using the samples
from this study we found that HDLox was significantly lower in both
trained groups compared to the untrained group (LT vs. OU: 0.6560.12
vs. 0.9160.17, p =,0.001; OT vs. OU: 0.6860.11vs. 0.9160.17,
p = 0.003), and LT and OT were not significantly different (p = 0.12).
doi:10.1371/journal.pone.0111716.g010
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vivo [12,58–60], due to certain biochemical limitations of the
DHR assay that have previously been described in detail [12,22],
only fresh apoB depleted serum samples and purified HDL
isolated by ultracentrifugation may be used with the DHR assay
and this may limit its utility for large scale clinical studies.
Recent interest has focused on the functional consequences of
HDL oxidation. High density lipoprotein is the major carrier of
lipid hydroperoxides in human blood plasma [34,35] We have
previously shown that increased lipid hydroperoxide (LOOH)
content is associated with dysfunctional HDL [51,61] and that
oxidized HDL is dysfunctional HDL [62–64]. Dysfunctional HDL
has increased endogenous ‘‘ROS load’’ and redox activity [65].
Oxidation could conceivably contribute to the formation of
dysfunctional HDL, proposed to be present in humans with
cardiovascular disease [12]. One potentially important pathway
for generating dysfunctional HDL via oxidation involves myelo-
peroxidase that mediates conversion of protein tyrosine residues to
3-chlorotyrosine, and methionine residues to methionine sulfoxide
(MetO) [66]. In addition, MetO can also be formed from exposure
of HDL’s major protein, apolipoprotein A-I (apoA-I) to H2O2 [67]
or lipid hydroperoxide [68], the latter generated during the
oxidation of HDL lipids. Reactive oxygen species (ROS) such as
1e-oxidants (i.e., hydroxyl radical and metal ions) have previously
been shown to oxidize tyrosine and methionine residues which can
have dramatic consequences on the functions of apoA-I/HDL,
including reverse cholesterol transport [69].
Herein we describe an approach to quantify the HDL redox
activity, a measure of HDL function, in a novel cell-free,
biochemical assay. We looked for a fluorescent probe that would
meet the following criteria i) would reliably and specifically
quantify the rate of lipid peroxidation of a specific amount of HDL
cholesterol ii) enzymatic amplification of the measurement of ROS
with this probe would overcome lipid-probe-ROS interactions that
may be a limitation of fluorescent biochemical assays of HDL
function [12,22] iii) would be a reasonable choice to measure ROS
accurately based on the known challenges and limitations that
most widely used fluorescent probes have for detecting and
measuring ROS [22].
Amplex red is a fluorogenic substrate with very low background
fluorescence, which reacts with H2O2 with a 1:1 stoichiometry to
Figure 11. The HDLox as measured with the novel assay is significantly associated with numerous anthropometric, metabolic and
physiological parameters in humans. HDLox was measured as described in Figure 2 and Figure S10 in a previous cohort of 100 humans looking
into the effect of exercise on metabolic and other physiological parameters. The values from HDLox for each subject are plotted against
representative physiological parameters such as Body Mass Index (BMI), subendocardial viability ratio (SEVR), a noninvasive measure of
subendocardial perfusion, C reactive protein (CRP) and oxidized Low Density Lipoprotein (ox-LDL).
doi:10.1371/journal.pone.0111716.g011
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produce highly fluorescent resorufin [70]. Amplex Red can be
oxidized by HRP which vastly increases the yield of resorufin
[35,41] and this assay is a reliable method to continuously measure
the extracellular formation of H2O2 [35,41] in 96 well plate format
[35,41]. We have previously used the Amplex Red reagent to
quantify ROS produced by oxidized lipids in cell culture
supernatants [34,35]. Indeed, Amplex Red in the presence of
the enzyme cholesterol oxidase has been reliably used to quantify
cholesterol content of HDL based on lipid peroxidation of HDL
[71]. Using a modification of this well described assay (Fig.1), we
demonstrate that Amplex Red, in the absence of cholesterol
oxidase and for the same amount of HDL cholesterol, can detect
differences in the rate of lipid peroxidation between different HDL
samples that correspond to differences in HDL function.
This approach in combination with immunoaffinity capture of
HDL for HDL isolation may overcome many confounding factors
that affected the readout in the previously described cell free assays
of HDL function and provides a measurement of HDLox that
correlates well with previously validated cell-based and cell-free
assays of HDL function. Because a large proportion of cholesterol
in blood is in the form of cholesteryl esters, cholesterol esterase is
used to produce free cholesterol from cholesterol esters [34,35]. In
addition the assay may be modified and cholesterol esterase may
or may not be added in the Amplex Red reagent so that
peroxidation of HDL cholesterol in the form of cholesteryl esters
versus free cholesterol can be determined [34,35].
This Amplex Red-based cell-free assay improves upon the prior
DHR-based cell-free assay. While also measuring the HDLox the
biochemistry of the Amplex Red fluorochrome and its ability to
detect lipid hydroperoxides is well established compared to DHR
[12,22]. In the absence of cholesterol oxidase the Amplex Red
detects the intrinsic hydroperoxide content of a specific amount of
HDL cholesterol and in the presence of HRP may overcome
previously described lipid-probe interactions [22]. In addition, the
Amplex Red -based assay improves upon the prior DCF-based
assay [13]. While DCF may also measure lipid peroxidation
[13,20,21], this earlier assay had several technical challenges that
have limited its utility. DCFH-DA is unstable and needs to be
dissolved in methanol for activation to the active molecule DCFH
which is prone to auto-oxidation and needs to be protected from
room air [41,72]. In contrast, Amplex Red is relatively stable, and
oxidizes at a predictable rate in the presence of HRP when
exposed to room air [41]. Furthermore, conversion of DCFH-DA
to DCFH can be mediated by esterases that are carried over
variably during the lipid purification process, adding another
variable that is difficult to control, while Amplex Red requires no
activation and is not prone to this effect [12,22,41]. Finally,
different diluents for biochemical assays of HDL function may
affect the oxidation rate of the indicator compound; this may also
explain the variability observed in the DCFH-DA assay between
different research groups [12]. In contrast, all the reagents used in
the Amplex Red assay are commercially available and thus this
assay can be better standardized. Moreover, the use of
immunoaffinity capture may allow HDL isolation and use of this
method in large scale studies and removal of much of the albumin
bound to the HDL particle that may alter the association of ROS
with lipoproteins [12,44], removes lipid peroxidation products
[45] and can also significantly interfere with the fluorescent
readout in biochemical assays of HDL function [22]. Finally, the
inter-assay variability of ,15% compares favorably with cell-
based assays of HDL function which have variability of .15%
[44].
In addition using animal models of atherosclerosis and 2
different human studies we show that this assay can be used as a
potential marker of cardiovascular disease and biologic processes
in vivo. The correlation of HDLox as measured by the Amplex
Red assay to the biologic readout of HDL in a cell-based assay is
consistent with a proposed mechanism whereby HDL exerts its
effects through modulating ROS [10,11], and suggests that the
assay accurately reflects HDL function. Further support for the
biological relevance of this measurement is the finding that for the
same amount of HDL cholesterol the HDLox was significantly
reduced in HDL from statin treated mice with atherosclerosis
compared to HDL from non-statin treated mice. Indeed,
treatment of these mice with statins has previously been shown
to reduce inflammatory properties of HDL [13] and we
demonstrate that the Amplex Red assay can detect the favorable
effect of statins on functional properties of HDL. In the pilot
human studies described in this manuscript we demonstrate the
ability of the Amplex Red Assay to measure HDLox and associate
cardiovascular and metabolic risk phenotypes with these measures
of HDL function. For example we confirmed previous data that
HDLox is associated with anthropometric parameters of obesity in
humans and cardiovascular disease in HIV-1 infected subjects
[3,4,12,58–60]. Moreover, the Amplex Red assay can detect
dysfunctional HDL in patients with HIV infection confirming our
previous results [32]. The fact that our assay quantifies HDLox
and that the HDLox levels correlate with surrogate measures of
cardiovascular disease and other physiological parameters in
humans such as obesity and insulin resistance increases its
applicability to biological samples, at least in the context of
cardiovascular diseases. This is because 1e-oxidants (i.e., hydroxyl
radical) contribute to oxidative modifications taking place in the
affected arterial wall during atherogenesis [12,22]. Thus, while
‘‘oxidized HDL’’ is not a chemically defined term, the oxidation
rate of Amplex Red corresponds to the intrinsic HDLox of specific
amount of HDL lipoproteins. However, we did not detect a
significant association between HDLox and progression of
subclinical atherosclerosis in a small group of healthy subjects.
This may have been explained by the relative small size of our
pilot study and the use of cryopreserved samples, especially since
the anti-oxidative capacity of HDL has been studied only in
association with clinically significant coronary artery disease in
larger studies [4,55,59,60]. However, in our exercise study of HIV
uninfected subjects with no known cardiovascular disease we did
show, for the first time to our knowledge, that HDLox correlated
significantly with subendocardial viability ratio (SEVR), a nonin-
vasive measure of subendocardial perfusion, C reactive protein
(CRP) and oxidized Low Density Lipoprotein (ox-LDL) which is
associated with the metabolic syndrome [58,73]. Larger case
control studies will further define the utility of this assay as a
marker of biologic processes and diseases in humans.
Finally, we showed that matrix effects, freeze thaw, sample
handling and long term storage of blood specimens at 280C can
affect the HDLox but the relative differences in HDLox between
different samples can still be reliably detected with the Amplex
Red reagent, in either serum or non EDTA plasma, fresh or
cryopreserved samples, and with up to 2 freeze-thaw cycles. We
also demonstrated that the HDLox readout can be normalized by
the HDL cholesterol amount and the assay can be standardized
using either an Amplex red stock solution of resorufin or a control
sample which is prepared from pooled HDL samples isolated from
plasma blood bank specimens. Since HDL is a lipoprotein and
under inflammatory conditions, it has been shown that both the
protein and phospholipid moieties of HDL are substantially
altered, thereby modifying the functional characteristics of the
HDL particles [1,2], normalization of the readout of assays of
HDL function by HDL protein content (determined by a BCA
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protein assay) [14,74] or plasma apolipoprotein A-I (apoA-I;
determined by ELISA) content has been suggested [20,75].
Normalization of the fluorescence readout (HDLox) by apoA-I
levels did not significantly affect the differences in HDLox between
HIV infected and uninfected groups compared to not normalizing.
However, the oxidative modifications occurring to HDL in the
diseased artery wall are conceivably more complex than in vitro
[76] and HDL is subject to continuous remodeling in vivo
[10,11,76–78]. This includes dissociation of apoA-I from the
lipoprotein particle, a process that could be increased by oxidation
[10,11,76–78] so it is unclear if the HDLox readout should be
normalized by apoA-1 levels or HDL protein levels especially since
the proteome of dysfunctional HDL has not been fully elucidated
[19]. Clearly, future studies are required to assess these various
aspects.
In conclusion, this new assay offers a rapid method for
measuring the redox properties of HDL. It yields results that
correlate well with previously validated cell-based and cell-free
assays of HDL function and can be used as a potential marker of
cardiovascular disease and biologic processes in humans. This new
technical approach may offer a convenient tool for studies of the
role of HDL functional phenotype in the development of
atherosclerosis in vivo.
Supporting Information
Figure S1 Flow diagram of Assay.
(TIF)
Figure S2 Without HRP lipid probe interactions are
present but increasing amounts of HRP can increase the
efficiency of detection of hydroperoxides carried by a
specific amount of HDL cholesterol. In a 96 well flat bottom
plate, 50 ul of 1X reaction buffer was added to each well alone or
with 5 mg (cholesterol) of apoB depleted serum (as determined by a
cholesterol assay) from a donor with anti-inflammatory HDL
(HDL) and from a donor with acute phase HDL (AP-HDL), each
in quadruplicates. 50 ml of HRP (0.5–4 U/ml) was then added to
all wells followed by incubation at 37uC for 60 min. 50 ml of
Amplex Red Reagent (final concentration 300 mM) was then
added to each well for a total volume of 150 ml and the rate of
production of resorufin was followed at 37uC in one-minute
intervals for 60 minutes. The rates of change in fluorescence
between 0 and 60 minutes are plotted for the quadruplicates, as
well as means/standard deviations. In the absence of HRP,
fluorescence quenching and lipid-probe interactions lead to
reduction in the fluorescence readout after addition of a specific
amount of HDL cholesterol compared to the fluorochrome alone,
consistent with our previous observations with other fluoro-
chromes such as DHR and DCF. Addition of $2 U/ml of HRP
lead to a specific amplification of the quantification of the
hydroperoxides associated with a specific amount of HDL
cholesterol. A representative sample from each type of HDL
(HDL vs AP-HDL) is shown and similar results were observed for
5 different other samples (5 HDL and 5 AP-HDL). In addition
similar results with HRP were observed when 5 mg of HDL
cholesterol isolated by FPLC or ultracentrifugation were added to
the reaction.
(TIFF)
Figure S3 Oxidation of Amplex Red and effect of added
HDL. In a 96 well flat bottom, 50 ml of 1X reaction buffer (0.5 M
potassium phosphate, pH 7.4, 0.25 M NaCl, 25 mM cholic acid,
0.5% Triton X-100) was added to each well alone or with 5 mg
(cholesterol) of apoB depleted serum (as determined by a
cholesterol assay) from a donor with anti-inflammatory HDL
(HDL) and from a donor with acute phase HDL (AP-HDL), each
in quadruplicates. 50 ml of HRP was then added to all wells
followed by incubation at 37uC for 60 min. 50 ml of Amplex Red
Reagent (final concentration 300 mM) was then added to each well
for a total volume of 150 ml. The rate of production of resorufin
was followed at 37uC in one-minute intervals using a fluorescence
microplate reader set to detect 530/590 nm excitation/emission.
A. The means and standard deviations of the quadruplicate
fluorescence measurements are plotted over time. B. The rates of
change in fluorescence between 0 and 60 minutes (calculated by
linear regression) are plotted for the quadruplicates, as well as
means/standard deviations. The background fluorescence of the
blank well (no HDL) was subtracted from the readout of each well
for each timepoint.
(TIF)
Figure S4 The Amplex Red assay can detect a concen-
tration dependent increase in the amount of hydroper-
oxides associated with increasing amount of added HDL
cholesterol. HDL isolated by ultracentrifugation was added in
varying concentrations (cholesterol) to 300 mM Amplex Red in a
96 well flat bottom plate and the rate of change in fluorescence
was measured as in Fig. 2 in the presence of 4 U/ml of HRP. The
rates of change in fluorescence (means and standard deviations)
are plotted against the amounts of added HDL. In addition similar
results with HRP were observed when HDL cholesterol isolated by
PEG precipitation was added to the reaction. There was a
concentration dependent increase in the fluorescent readout with
increasing amount of added HDL cholesterol in the presence of
HRP in contrast to a concentration dependent decrease in the
readout with increasing amount of added HDL cholesterol with
other fluorescent probes (DCF and DHR).
(TIFF)
Figure S5 Low inter-assay variability between measure-
ments of HDL effects. Rate of oxidation of Amplex Red in the
presence of six different samples of HDL isolated by PEG
precipitation from 6 subjects (3 HIV infected subjects with AP-
HDL and 3 healthy subjects with normal HDL) was assessed as
described in Fig. 2, using 5 mg (cholesterol) of added HDL. The
data (means of quadruplicates) from four independent experiments
are plotted. The mean inter-assay variability for these six samples
was 8.6% (range 4.9 to 9.7%), and the mean intra-assay variability
was 4.6% (range 2.9–7.2%). When HDL from the same subjects
was isolated by UC (not plotted) the mean inter-assay variability
for these six samples was 10.6% (range 6.9 to 12.6%), and the
mean intra-assay variability was 6.8% (range 4.8–9.1%). In
addition, measurement of the rate of oxidation of Amplex Red
over 60 min lead to reduced experimental variability compared to
endpoint measurement of fluorescence at 60 min.
(TIFF)
Figure S6 Correlation of effect of HDL on Amplex Red
oxidation using different methods of HDL isolation.
HDL was isolated by ultracentrifugation or PEG precipitation
from 5 HIV infected patients known to have acute phase HDL
(AP-HDL; shown in solid black circles) and 5 patients with normal
HDL (shown in white circles). 5 ug of HDL cholesterol was then
added to 300 mM Amplex Red in a 96 well flat bottom plate and
the rate of change in fluorescence was measured as in Fig. 2 in the
presence of 4 U/ml of HRP. The mean rates of change in
fluorescence are plotted.
(TIFF)
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Figure S7 Commercially available resorufin standards
can be used to standardize fluorescence-based quantifi-
cation of the hydroperoxide content of a specific amount
of HDL cholesterol. A commercially available resorufin
fluorescence reference standard can be used to prepare a standard
curve to determine the moles of fluorescent product produced in the
Amplex Red reaction according to the manufacturer’s instructions.
Endpoint measurement of the fluorescence signal that corresponds
to production of resorufin and oxidation of the Amplex Red reagent
was performed at 60 minutes as described in Fig. 2. The reference
2 mM resorufin standard was diluted accordingly to generate a
standard curve of resorufin that would ‘‘fit’’ the dynamic range of
the measured fluorescence at 60 minutes for the specific assay.
Towards this end, the amount of the added cholesterol and the time
of the reaction for certain photomultiplier sensitivity needs to be
titrated carefully. The triplicate fluorescence readings for each
standard were averaged and the mean fluorescence was calculated.
The average fluorescence of the blank sample (Amplex Red alone
without HDL) was subtracted from all the standards and samples
and the adjusted fluorescence was calculated. The adjusted
fluorescence of the standards was plotted as a function of the
concentration of the resorufin standards. An example of a standard
curve with a dynamic range 15.625–500 nM and six standards is
shown. The fluorescence of the HDL samples was calculated in the
presence of 5 mg (cholesterol) of added HDL. HDL was isolated by
PEG precipitation from HIV infected subjects with acute phase
HDL (AP-HDL) and healthy subjects with normal HDL. The
means of quadruplicates were calculated (adjusted fluorescence).
The amount of produced resorufin for each HDL sample was
calculated using the equation obtained from the linear regression of
the standard curve substituting adjusted fluorescence values for each
sample. 2 representative samples (one with normal HDL [dashed
line] and one with AP-HDL [solid line]) are shown. Since the
resorufin standards are run in parallel with the samples over
60 minutes the slope of change in fluorescence per min (FU/min)
can be converted into the slope of nM of resorufin produced per min
(nM/min). Thus, using this approach, the resorufin concentration
that is produced as a result of the specific oxidation of the Amplex
Red Reagent by the hydroperoxides present in a specific amount of
each HDL cholesterol sample, can be measured and can be used as
a surrogate measure of the HDL redox activity and HDL function.
(TIFF)
Figure S8 The fluorescence readout of the Amplex Red
assay of HDL function can be normalized against the
readout of a specific amount of HDL cholesterol isolated
from pooled apoB depleted serum of healthy subjects. A)
The Amplex Red oxidation rate (AROR) was determined as
described in Fig. 2 after adding 5 mg of apoB depleted serum
(isolated by PEG precipitation) from 50 cryopreserved serum
blood bank specimens from healthy subjects. The values represent
means of triplicate samples. There was an approximately 3-fold
difference between the lowest and highest AROR value (median
155, IQR 119–180 FU/min; range 74–246 FU/min). B) The 50
HDL samples were pooled in groups of five samples (pentads;
0.5 mg of HDL cholesterol from each sample) so that the total
amount of HDL cholesterol in each pooled sample (pentad) was
5 mg, for a total of 10 pentads. Then the pentads were combined in
various combinations and different number (5, 10, 15, 20, 25, 30,
35, 40, 45, 50) of HDL samples so that the total amount of HDL
cholesterol at each pooled sample would be 5 mg. The AROR was
determined as described in Fig. 2. The values represent means of
triplicate samples. Using this methodology there was approxi-
mately a 2-fold reduction in the variability of determination of the
AROR (for the same amount of HDL cholesterol) in healthy
subjects (median 153, IQR 141–166 FU/min; range 120–
186 FU/min). Thus, to correct for interassay variability across
different plates and to standardize the assay, a pooled HDL
control sample from at least 30 healthy volunteers may be included
in each plate, AROR can be determined and sample fluorescence
values may be normalized by this pooled value. The individual
normalized AROR (nAROR) [nAROR = (AROR/AROR
control] is evaluated as a ratio to the AROR of a control HDL
isolated from the pooled serum. Thus, using this method we avoid
expression of results of AROR in arbitrary units (FU/min) and
results between different studies can be comparable provided the
same pooled control is used.
(TIFF)
Figure S9 A specific amount of HDL cholesterol isolated
from pooled blood bank specimens of healthy subjects
can be used as a universal control to standardize the
Amplex Red assay of HDL function. HDL was isolated using
PEG precipitation from 3 different groups (A, B, C; each 30
samples) of cryopreserved serum blood bank specimens. The HDL
samples in each group were pooled as described in Fig. S6 (three
different blood bank pools). The Amplex Red oxidation rate
(AROR) was determined as described in Materials and Methods.
The mean AROR among the 3 different blood bank pools was
comparable. Thus, this current approach may be used to create a
universal control for determination of DOR by combining HDL
samples from at least 30 different donors.
(TIFF)
Figure S10 The HDL concentration as determined by
the clinical laboratory can be used to adjust the
fluorescence readout for the amount of HDL cholesterol
in each sample in the Amplex Red assay of HDL
function. ApoB depleted serum was isolated by PEG precipita-
tion from 20 subjects (10 healthy and 10 with HIV infection and
acute phase HDL). The Amplex Red oxidation rate (AROR) was
determined as described in Fig. 2 and HDL was added using two
different methods (A and B). In method A the HDL cholesterol
concentration of each sample was determined using a cholesterol
assay as described in the Methods section and then 5 mg of HDL
cholesterol was added to each well. The individual normalized
AROR (nAROR) [nAROR = (AROR/AROR control] is a
measure of the HDL redox activity (HRA) and is evaluated as a
ratio to the AROR of a control HDL isolated from pooled serum
as described in Fig. S7. In Method B the HDL cholesterol
concentration of each sample (mg/dl) was measured by the clinical
lab and this value is routinely available in the setting of standard
clinical care. A specific volume of apoB depleted serum (50 ml) was
added to each well, the AROR for each sample was determined as
above and this readout was normalized by the HDL cholesterol
concentration of each sample (nHDLAROR). A control HDL
sample was created after pooling equal volumes of apoB depleted
serum from 30 healthy blood bank serum. The HDL concentra-
tion of this pooled HDL control was calculated from the HDL
concentrations of the individual samples (measured in mg/dl by
the clinical lab) and the fluorescence readout was normalized by
this value (nHDLAROR control). The individual normalized to
control AROR is evaluated as a ratio to the AROR of a control
HDL isolated from pooled serum [nAROR = (nHDLAROR/
nHDLAROR control]. The values represent means of triplicate
samples and the correlation coefficient is shown. Data from
healthy subjects are shown as white circles and data from HIV
infected subjects are shown as gray circles.
(TIFF)
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Figure S11 The standardization method with the pooled
control minimizes the effect of multiple freeze-thaw
cycles on determination of HDL redox activity (HRA)
using the Amplex Red assay. Oxidation rate of Amplex Red
(AROR) in the presence of 20 different samples of HDL isolated
by PEG precipitation from heparin plasma [10 from patients with
Human Immunodeficiency virus (HIV-1) infection and 10 from
healthy volunteers (Non HIV)] was assessed as described in
Methods and in Fig. 2, using 2.5 mg (cholesterol) of added HDL.
The AROR of each sample was determined within 6 hours after
collection of the blood specimen and after 1–5 freeze-thaw cycles.
The values represent means of triplicate samples. The % relative
HRA of each HDL sample after each extra freeze-thaw cycle (for
up to 5 cycles) was significantly higher (paired t-test p,0.05 for all
datapoints) compared to the HDL sample that was isolated within
6 hours. Although the HRA values tended to significantly increase
after each extra freeze-thaw, their correlations with the HRA
value from the HDL sample that was isolated within 6 hours
remained statistically significant (p,0.05 for all data points). In
addition, the individual normalized AROR was evaluated as a
ratio to the AROR of a control HDL isolated from pooled serum
as described in Figs S7 and S9. The control HDL matched the
freeze-thaw cycles of the respective HDL samples (for example if
the samples were thawed once the pooled control was made from
HDL samples that were thawed once, etc). This standardization
method improved the correlations of the relative HRA values with
the HRA value from the HDL sample that was isolated within
6 hours and tended to minimize the effect of multiple freeze-thaw
cycles on determination of HRA.
(TIFF)
Figure S12 The standardization method minimizes the
effect of different matrices on oxidative properties of
HDL. Oxidation rate of Amplex Red (AROR) in the presence of
13 different samples of HDL [7 from patients with Human
Immunodeficiency virus (HIV-1) infection and 6 from healthy
volunteers (Non HIV)] isolated by PEG precipitation from heparin
plasma, citrate plasma and serum was assessed as described in
Methods and in Fig. 2. The values represent means of all the
samples. The HRA values from plasma citrate samples correlated
significantly (p,0.01) with the HRA values from serum samples
but heparin interfered with the readout. In addition, the HRA of
each sample was normalized by the HRA value of the control
sample and the % relative HRA was determined as in Fig. S10.
The suggested standardization method improved the correlations
of the HRA values and tended to minimize the effect of different
matrices on determination of HRA.
(TIFF)
Figure S13 Long term storage of blood specimens tends
to increase HDL redox activity (HRA) as determined by
the Amplex Red assay but the results are comparable
between different timepoints. The Multicenter AIDS Cohort
Study (MACS) has defined a group of men who remained HIV-1-
seronegative despite hundreds to thousands of high-risk sexual
exposures in the 1980s. The MACS cohort recruited men in 1985
for natural history studies (Am J Epidemiol 126: 310-8), and has
continued to follow subjects every 6 months to the present. Using 9
stored serum samples from this cohort that were stored for 27 and
28 years at 280uC, we determined the effect of long term storage
at280C on HDL redox activity (HRA) as described in Fig. 2. The
readout of each sample was expressed as % relative to the average
readout of all 9 samples at 27 years of cryopreservation. The HRA
as determined by the Amplex Red assay significantly increased
after cryopreservation for one extra year (125641% vs 100631%,
p value for paired t test = 0.04) and the readouts from the 2 groups
correlated significantly (r = 0.69, p,0.01).
(TIFF)
Figure S14 HDL isolated using immunoaffinity capture
of HDL is largely free of albumin. 50 ul of plasma (n= 10)
was added into 96 wells and was isolated using immunoaffinity
capture of HDL according to the manufacturer’s instructions (Kit
A). After 5 washes, 300 ml of albumin bromocresol green reaction
(BCG) reagent (Thermo Scientific Inc) were added to each well
and after 90 second incubation at 37uC the optical density at
630 nm was read. Results are expressed as % relative value
compared to the positive control (50 ml of plasma). The median
relative albumin content bound to HDL was 0.90% with the BCG
method, one of the most sensitive and specific methods to detect
albumin. The minimal detection of HDL-bound albumin (,0.5%
relative to the positive control) was also confirmed with a
secondary antibody against albumin conjugated to horseradish
peroxidase (HRP) (Pierce Inc). Similar results were obtained with
Kit B.
(TIFF)
Table S1 Outline of protocol used to measure HDL lipid
peroxidation (PEG method for HDL isolation).
(DOCX)
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